The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...

BTIG analyst Justin Zelin has reiterated their bullish stance on SNDX stock, giving a Buy rating on November 15.Don't Miss our Black Friday ...

Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...

Syndax Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or ...

Two separate shootings disrupted a "second line" parade in New Orleans' St Roch neighborhood, claiming the lives of two individuals and leaving nine others injured. The incidents, occurring 45 ...

Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors. The treatment, Rejuforj, will be available as soon as this month for patients with an ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Nov. 15, 2024 — More time spent sitting, reclining or lying down during the day may increase the risk of cardiovascular disease (CVD) and death, according to a new study. More than roughly 10 ...